Association Clinique et Thérapeutique Infantile du Val-de-Marne, Créteil, France.
Groupe de Pathologie Infectieuse Pédiatrique, Paris, France.
Clin Infect Dis. 2021 Apr 26;72(8):1453-1456. doi: 10.1093/cid/ciaa917.
We aimed to assess the invasive disease potential of non-PCV13 serotypes after the implementation of this vaccine. Most non-PCV13 serotypes had low invasive disease potential. Among serotypes with the highest invasive disease potential (12F, 24F, 38, 8, 33F, 22F, and 10A), all but 24F and 38 were included in PCV20.
我们旨在评估该疫苗实施后非 13 价肺炎球菌结合疫苗（PCV13）血清型的侵袭性疾病潜力。大多数非 13 价 PCV 血清型侵袭性疾病潜力较低。在侵袭性疾病潜力最高的血清型（12F、24F、38、8、33F、22F 和 10A）中，除 24F 和 38 外，其他血清型均包含在 20 价肺炎球菌结合疫苗（PCV20）中。
